Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTRA-9620 in infants with short bowel syndrome on parenteral nutrition
2015-000181-60Phase 2Active
- Sponsor
- Nutrinia
- Start
- Feb 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NTRA-9620 in short bowel syndrome (SBS) and intestinal malabsorption (3 arms), sponsored by Nutrinia. Primary endpoints: Percent change in parenteral nutrition requirements at 12 weeks and Percent change in parenteral nutrition requirements at 24 weeks. Started Feb 2017; status: active.
02
Drugs
NTRA-9620
03
Conditions
short bowel syndrome (SBS)intestinal malabsorption
Beyond the preview
Go deeper on 2015-000181-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000181-60.